Table of contents

• Overview of the clinical research
• Target population and condition studied
• Trial design and phase
• Main outcomes and what they measure
• Treatment plan studied in the trial
• Trial status and enrollment

Overview of the clinical research

The available clinical trial is studying Autologous Human Adipose Perivascular Stromal Cells Genetically Modified To Secrete Soluble Tumour Necrosis Factor-Related Apoptosis-Inducing Ligand in a patient group with pancreatic cancer.^[1] The trial is focused on a product called RR001 and is designed to look at both safety and early signs of efficacy when used with standard chemotherapy.^[1]

Target population and condition studied

The condition studied is ductal adenocarcinoma of the pancreas, including locally advanced, non-resectable pancreatic adenocarcinoma.^[1] “Locally advanced” means the cancer has grown in the area around the pancreas, and “non-resectable” means it cannot be removed by surgery.^[1]

The trial is aimed at patients with this specific pancreatic cancer population, rather than at people with a wide range of cancers.^[1]

Trial design and phase

This study is an interventional trial, which means the researchers actively give a treatment and observe what happens.^[1] It is a Phase 1/2 trial, so it combines early safety testing with an initial look at whether the treatment may help.^[1]

The title describes the study as open label and non-randomized.^[1] Open label means both the research team and the participants know which treatment is being given, and non-randomized means people are not assigned by chance to different treatment groups.^[1]

Main outcomes and what they measure

The main outcome is the safety of intratumoral injections of RR001 given by ultrasound-guided injection together with standard therapy based on GEM/Nab-PTX.^[1] In simple terms, the study wants to see whether giving the treatment directly into the tumor can be done safely in this setting.^[1]

The study also aims to establish the maximal tolerated dose (MTD) and the recommended phase IIb dose (RP2D) after three dose levels are delivered.^[1] MTD is the highest dose that can be given without unacceptable problems, and RP2D is the dose chosen for later studies.^[1]

The brief summary repeats that the trial is designed to determine safety and to define MTD and RP2D while RR001 is used with standard chemotherapy.^[1]

Treatment plan studied in the trial

The intervention list includes RR001 given by intratumoral use, meaning it is injected into the tumor itself.^[1] The study also includes standard chemotherapy drugs: Gemsol and Abraxane, both given intravenously, which means through a vein.^[1]

The trial title and summary show that RR001 is tested in combination with standard of care therapy based on GEM/Nab-PTX.^[1] This means the research is not only looking at RR001 alone, but at how it works when added to the usual chemotherapy approach used in the study.^[1]

Trial status and enrollment

The trial status is Authorised.^[1] The planned enrollment is 18 participants, which shows this is a small early-stage study.^[1]

Because the study is small and early, its main purpose is to collect first information on safety, dose finding, and early treatment activity in the target pancreatic cancer group.^[1]